Spina Bifida Market Research Report- Forecast to 2023
ID: MRFR/HC/4188-HCRR | November, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports
Spina Bifida Market Research Report: By Type (Occulta, Closed Neural Tube Defects, Meningocele, Myelomeningocele), By Diagnosis (Blood Test, Ultrasound, Amniocentesis), Treatment (Medical Procedure, Surgeries), By End User – Global Forecast Till 2023
Market Scenario
Spina bifida is a congenital disorder that results in the malformation of the spinal cord. The condition is more common among Hispanics and whites, and the prevalence females are more likely to get affected than males.
On considering historical prevalence data of spina bifida in northeast China, during 2006-2015, it is found that a total of 2,029 cases of spina bifida were identified from 3,248,954 live births i.e. 6.25/10,000 live births. The disease is found to be highly prevalent in Chaoyang, Fuxin, and Huludao cities of China. According to the 2013 study conducted by Healthcare Cost and Utilization Project, hospitalization cost related to spina bifida was more than USD 600 million in 2013 for people of all ages.
It is noted that rising technological advancements is the key factor driving the spina bifida market. With the rising awareness about the disease, market players are coming up with innovations owing to technological advancements. For instance, in Nov 2015, B. Braun Melsungen AG announced the launch of Ster-ASSIST Sterile Peripheral IV Catheter Insertion Kit. In the same year, Medtronic acquired Twelve, Inc., a developer of trans-catheter mitral valve replacement device.
Various other factors such as growing awareness, increased incidence of spina bifida, related complications, unmet medical needs, improving regulatory framework, increasing adoption rate, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global spina bifida market.
Despite these drivers, there are some issues associated with spina bifida market. The cost of treatment, side-effects of surgeries, and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
It is estimated that the spina bifida market is expected to grow at a CAGR 8.0% during the forecast period of 2017-2023.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience
- Pharmaceutical Companies
- Medical Device Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Segmentation
The global spina bifida market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is classified as occulta, closed neural tube defects, meningocele, and myelomeningocele.
On the basis of the diagnosis, the market is classified as blood tests, ultrasound, amniocentesis, and others. The blood tests segment is further classified as maternal serum alpha-fetoprotein (MSAFP) test, test to confirm high AFP levels, and other blood tests.
On the basis of the treatment, the market is classified as medical procedure, surgery, oral medications, and others. The medical procedure is further segmented into urinary catheterization, urinary diversion, and enema. The surgery is further segmented into spine surgery, fetal endoscopic surgery, spinal fusion, suprapubic cystostomy, and caesarean section. The oral medications is further segmented into antibiotics, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the spina bifida market owing to the rising occurrence of spina bifida in this region, and technological advancements. According to the statistics suggested by Centers for Disease Control and Prevention (CDC), around 1,500 babies are born with spina bifida every year in the United States. It is also reported that Hispanic women are the most vulnerable population for this disease as compared to non-Hispanic black or non-Hispanic white women.
Europe holds the second position in the spina bifida market. It is expected that the government support towards research & development expenditure, and amendments in reimbursement policies in the healthcare is likely to drive the European spina bifida market.
Asia Pacific is the fastest growing spina bifida market owing to a huge patient pool and development in healthcare technology. Healthcare expenditure is found to be improving in various Asia Pacific regions. According to the data suggested by Australian Institute of Health and Welfare during the year 2015-16, the total health expenditure was USD 170.4 billion i.e. 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.
Key Players
Some of key the players in the global spina bifida market are B. Braun Melsungen AG, Boston Scientific, C.B. Fleet, C.R. Bard, Inc., Coloplast A/S, ConvaTec Group plc, Cook Medical, Covidien Private Ltd., Dynarex Corporation, Ethicon, Fujifilm, Hollister Incorporated, KARL STORZ, Medline Industries, Medtronic plc, Olympus, Pacific Hospital Supply Co., Ltd., Smith & Nephew, Stryker, Teleflex Incorporation, Wellspect Healthcare, and others.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Spina Bifida Market, by Type
6.1 Introduction
6.2 Occulta
6.2.1 Market Estimates & Forecast, 2017 – 2023
6.3 Closed Neural Tube Defects
6.3.1 Market Estimates & Forecast, 2017 – 2023
6.4 Meningocele
6.4.1 Market Estimates & Forecast, 2017 – 2023
6.5 Myelomeningocele
6.5.1 Market Estimates & Forecast, 2017 – 2023
Chapter 7. Global Spina Bifida Market, by Diagnosis
7.1 Introduction
7.2 Blood Tests
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Ultrasound
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Amniocentesis
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Others
7.5.1 Market Estimates & Forecast, 2017 – 2023
Chapter 8. Global Spina Bifida Market, by treatment
8.1 Introduction
8.2 Medical Procedure
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Surgery
8.3.1 Market Estimates & Forecast, 2017 – 2023
8.4 Oral Medications
8.4.1 Market Estimates & Forecast, 2017 – 2023
8.5 Others
8.5.1 Market Estimates & Forecast, 2017 – 2023
Chapter 9. Global Spina Bifida Market, by End User
9.1 Introduction
9.2 Hospitals
9.2.1 Market Estimates & Forecast, 2017 – 2023
9.3 Clinics
9.3.1 Market Estimates & Forecast, 2017 – 2023
9.4 Diagnostic Centers
9.4.1 Market Estimates & Forecast, 2017 – 2023
9.5 Drug Stores
9.5.1 Market Estimates & Forecast, 2017 – 2023
9.6 Pharmacies
9.6.1 Market Estimates & Forecast, 2017 – 2023
9.7 Others
9.7.1 Market Estimates & Forecast, 2017 – 2023
Chapter 10. Global Spina Bifida Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 B. Braun Melsungen AG
12.1.1 Company Overview
12.1.2 Types Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Boston Scientific
12.2.1 Company Overview
12.2.2 Types Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Cook Medical
12.3.1 Company Overview
12.3.2 Types Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Ethicon
12.4.1 Company Overview
12.4.2 Types/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 KARL STORZ
12.5.1 Company Overview
12.5.2 Types Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 KARL STORZ Private Limited
12.6.1 Company Overview
12.6.2 Types Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 MEDLINE INDUSTRIES
12.7.1 Overview
12.7.2 Types Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Spina Bifida industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Spina Bifida Industry Synopsis, 2017 – 2023
Table 2 Spina Bifida Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Spina Bifida Market by Region, 2017 – 2023, (USD Million)
Table 4 Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 5 Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 6 Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 7 Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 9 North America Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 10 North America Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 11 North America Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 12 US Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 13 US Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 US Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 15 US Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 16 Canada Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 17 Canada Spina Bifida market by Diagnosis, 2017 – 2023, (USD Million)
Table 18 Canada Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 19 Canada Spina Bifida market by End Users, 2017 – 2023, (USD Million)
Table 20 South America Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 21 South America Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 23 South America Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 24 Europe Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 25 Europe Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Europe Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Europe Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 28 Western Europe Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 29 Western Europe Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 30 Western Europe Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 31 Western Europe Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Spina Bifida market by Diagnosis, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Spina Bifida Market by End Users, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Spina Bifida market by End Users, 2017 – 2023, (USD Million)
Table 40 The Middle East & Africa Spina Bifida Market by Type, 2017 – 2023, (USD Million)
Table 41 The Middle East & Africa Spina Bifida Market by Diagnosis, 2017 – 2023, (USD Million)
Table 42 The Middle East & Africa Spina Bifida Market by Treatment, 2017 – 2023, (USD Million)
Table 43 The Middle East & Africa Spina Bifida market by End Users, 2017 – 2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Spina Bifida Market
Figure 3 Segmentation Market Dynamics for Spina Bifida Market
Figure 4 Global Spina Bifida market Share, by Type 2016
Figure 5 Global Spina Bifida market Share, by Diagnosis 2016
Figure 6 Global Spina Bifida market Share, by Treatment 2016
Figure 7 Global Spina Bifida market Share, by End Users, 2016
Figure 8 Global Spina Bifida market Share, by Region, 2016
Figure 9 North America Spina Bifida market Share, by Country, 2016
Figure 10 Europe Spina Bifida market Share, by Country, 2016
Figure 11 Asia Pacific Spina Bifida market Share, by Country, 2016
Figure 12 Middle East & Africa Spina Bifida market Share, by Country, 2016
Figure 13 Global Spina Bifida market: Company Share Analysis, 2016 (%)
Figure 14 B. Braun Melsungen AG : Key Financials
Figure 15 B. Braun Melsungen AG Segmental Revenue
Figure 16 B. Braun Melsungen AG : Geographical Revenue
Figure 17 Boston Scientific: Key Financials
Figure 18 Boston Scientific: Segmental Revenue
Figure 19 Boston Scientific: Geographical Revenue
Figure 20 Cook Medical: Key Financials
Figure 21 Cook Medical: Segmental Revenue
Figure 22 Cook Medical: Geographical Revenue
Figure 23 Ethicon: Key Financials
Figure 24 Ethicon: Segmental Revenue
Figure 25 Ethicon: Geographical Revenue
Figure 26 KARL STORZ: Key Financials
Figure 27 KARL STORZ: Segmental Revenue
Figure 28 KARL STORZ Geographical Revenue
Figure 29 KARL STORZ Private Limited: Key Financials
Figure 30 KARL STORZ Private Limited: Segmental Revenue
Figure 31 KARL STORZ Private Limited: Geographical Revenue
Figure 32 MEDLINE INDUSTRIES: Key Financials
Figure 33 MEDLINE INDUSTRIES: Segmental Revenue
Figure 34 MEDLINE INDUSTRIES: Geographical Revenue
